Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 405

The DOI matches its Crossref record; 443 of the 443 references it cites were found in a registry or an index.

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Open access
Abdelhamid, Asmaa S, Brown, Tracey J, Brainard, Julii S, Biswas, Priti, Thorpe, Gabrielle C, Moore, Helen J, Deane, Katherine HO, AlAbdulghafoor, Fai K, Summerbell, Carolyn D, Worthington, Helen V, Song, Fujian, Hooper, Lee·2018·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Researchers have suggested that omega-3 polyunsaturated fatty acids from oily fish (long-chain omega-3 (LCn3), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), as well as from plants (alpha-linolenic acid (ALA)) benefit cardiovascular health. Guidelines recommend increasing omega-3-rich foods, and sometimes supplementation, but recent trials have not confirmed this. OBJECTIVES: To assess effects of increased intake of fish- and plant-based omega-3 for all-cause mortality, cardiovascular (CVD) events, adiposity and lipids. SEARCH METHODS: We searched CENTRAL, MEDLINE and Embase to April 2017, plus ClinicalTrials.gov and World Health Organization International Clinical Trials Registry to September 2016, with no language restrictions. We handsearched systematic review references and bibliographies and contacted authors. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that lasted at least 12 months and compared supplementation and/or advice to increase LCn3 or ALA intake versus usual or lower intake. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed studies for inclusion, extracted data and assessed validity. We performed separate random-effects meta-analysis for ALA and LCn3 interventions, and assessed dose-response relationships through meta-regression. MAIN RESULTS: We included 79 RCTs (112,059 participants) in this review update and found that 25 were at low summary risk of bias. Trials were of 12 to 72 months' duration and included adults at varying cardiovascular risk, mainly in high-income countries. Most studies assessed LCn3 supplementation with capsules, but some used LCn3- or ALA-rich or enriched foods or dietary advice compared to placebo or usual diet. LCn3 doses ranged from 0.5g/d LCn3 to > 5 g/d (16 RCTs gave at least 3g/d LCn3).Meta-analysis and sensitivity analyses suggested little or no effect of increasing LCn3 on all-cause mortality (RR 0.98, 95% CI 0.90 to 1.03, 92,653 participants; 8189 deaths in 39 trials, high-quality evidence), cardiovascular mortality (RR 0.95, 95% CI 0.87 to 1.03, 67,772 participants; 4544 CVD deaths in 25 RCTs), cardiovascular events (RR 0.99, 95% CI 0.94 to 1.04, 90,378 participants; 14,737 people experienced events in 38 trials, high-quality evidence), coronary heart disease (CHD) mortality (RR 0.93, 95% CI 0.79 to 1.09, 73,491 participants; 1596 CHD deaths in 21 RCTs), stroke (RR 1.06, 95% CI 0.96 to 1.16, 89,358 participants; 1822 strokes in 28 trials) or arrhythmia (RR 0.97, 95% CI 0.90 to 1.05, 53,796 participants; 3788 people experienced arrhythmia in 28 RCTs). There was a suggestion that LCn3 reduced CHD events (RR 0.93, 95% CI 0.88 to 0.97, 84,301 participants; 5469 people experienced CHD events in 28 RCTs); however, this was not maintained in sensitivity analyses - LCn3 probably makes little or no difference to CHD event risk. All evidence was of moderate GRADE quality, except as noted.Increasing ALA intake probably makes little or no difference to all-cause mortality (RR 1.01, 95% CI 0.84 to 1.20, 19,327 participants; 459 deaths, 5 RCTs),cardiovascular mortality (RR 0.96, 95% CI 0.74 to 1.25, 18,619 participants; 219 cardiovascular deaths, 4 RCTs), and CHD mortality (1.1% to 1.0%, RR 0.95, 95% CI 0.72 to 1.26, 18,353 participants; 193 CHD deaths, 3 RCTs) and ALA may make little or no difference to CHD events (RR 1.00, 95% CI 0.80 to 1.22, 19,061 participants, 397 CHD events, 4 RCTs, low-quality evidence). However, increased ALA may slightly reduce risk of cardiovascular events (from 4.8% to 4.7%, RR 0.95, 95% CI 0.83 to 1.07, 19,327 participants; 884 CVD events, 5 RCTs, low-quality evidence with greater effects in trials at low summary risk of bias), and probably reduces risk of arrhythmia (3.3% to 2.6%, RR 0.79, 95% CI 0.57 to 1.10, 4,837 participants; 141 events, 1 RCT). Effects on stroke are unclear.Sensitivity analysis retaining only trials at low summary risk of bias moved effect sizes towards the null (RR 1.0) for all LCn3 primary outcomes except arrhythmias, but for most ALA outcomes, effect sizes moved to suggest protection. LCn3 funnel plots suggested that adding in missing studies/results would move effect sizes towards null for most primary outcomes. There were no dose or duration effects in subgrouping or meta-regression.There was no evidence that increasing LCn3 or ALA altered serious adverse events, adiposity or lipids, except LCn3 reduced triglycerides by ˜15% in a dose-dependant way (high-quality evidence). AUTHORS' CONCLUSIONS: This is the most extensive systematic assessment of effects of omega-3 fats on cardiovascular health to date. Moderate- and high-quality evidence suggests that increasing EPA and DHA has little or no effect on mortality or cardiovascular health (evidence mainly from supplement trials). Previous suggestions of benefits from EPA and DHA supplements appear to spring from trials with higher risk of bias. Low-quality evidence suggests ALA may sli

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd003177.pub4

Cites

443 of 443 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 443 references

Research works printed but not linked: 83

  1. Geleijnse, 2011, Effects of n-3 fatty acids on cognitive decline: a randomized double-blind, placebo-controlled trial in stable myocardial infarction patients, Alzheimer's & Dementia, 1, S512, 10.1016/j.jalz.2011.05.1432 · DOI
  2. Brouwer, 2013, Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the alpha omega trial, PLOS ONE, 8, e81519, 10.1371/journal.pone.0081519 · DOI
  3. Eussen, 2012, Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction, European Heart Journal, 33, 1582, 10.1093/eurheartj/ehr499 · DOI
  4. Geleijnse, 2011, Effects of n-3 fatty acids on cognitive decline: A randomized double-blind, placebo-controlled trial in stable myocardial infarction patients, Alzheimer's & Dementia, 1, S512, 10.1016/j.jalz.2011.05.1432 · DOI
  5. Geleijnse, 2012, Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients, Alzheimer's & Dementia, 8, 278, 10.1016/j.jalz.2011.06.002 · DOI
  6. Geleijnse, 2010, Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial, American Heart Journal, 159, 539, 10.1016/j.ahj.2009.12.033 · DOI
  7. Giltay, 2012, No effects of n-3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial, International Journal of Andrology, 35, 680, 10.1111/j.1365-2605.2012.01255.x · DOI
  8. Giltay, 2011, Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction, American Journal of Clinical Nutrition, 94, 1442, 10.3945/ajcn.111.018259 · DOI
  9. Hoogeveen, 2012, Effects of N-3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial, Nephrology Dialysis Transplantation, 27, ii64
  10. Hoogeveen, 2014, No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial, European Journal of Preventive Cardiology, 21, 1429, 10.1177/2047487313494295 · DOI
  11. Hoogeveen, 2014, Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial, Clinical Journal of The American Society of Nephrology: CJASN, 9, 1676, 10.2215/CJN.10441013 · DOI
  12. Kromhout, 2011, N-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes, Diabetes Care, 34, 2515, 10.2337/dc11-0896 · DOI
  13. Kromhout, 2010, N-3 fatty acids and cardiovascular events after myocardial infarction, New England Journal of Medicine, 363, 2015, 10.1056/NEJMoa1003603 · DOI · Paper page
  14. Burr, 1989, Fish and the heart, Lancet, ii, 1451
  15. Harrison, 2005, Dietary Intervention for Maintaining Sinus Rhythm Following Cardioversion for Atrial Fibrillation: a Randomised Controlled Trial [PhD thesis]
  16. Harrison, 2003, Using community-based dietary assistants to increase the intake of oil-rich fish among older people, European Journal of Public Health, 13, 105
  17. Doi, 2014, Clinical outcomes of early initiation of pure eicosapentaenoic acid supplement after percutaneous coronary intervention in patients with acute coronary syndrome, European Heart Journal, 35, 1156
  18. Feagan, 2008, Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials, JAMA, 229, 1690, 10.1001/jama.299.14.1690 · DOI · Paper page
  19. Erdogan, 2007, Omega AF study: polyunsaturated fatty acids (PUFA) for prevention of atrial fibrillation relapse after successful external cardioversion, Heart Rhythm, 4, S185
  20. Edel, 2013, Flaxseed lignan metabolites elicit antihypertensive effects in pad patients in the flax-pad trial, Annals of Nutrition and Metabolism, 63, 1339
  21. Pierce, 2014, The use of dietary flaxseed to promote cardiovascular health, Acta Physiologica, 211, 15
  22. Pierce, 2013, The clinical use of flaxseed as a powerful nutritional intervention to treat cardiovascular disease, Cardiology (Switzerland), 126, 201
  23. Gill, 2014, Omega-3 fatty acids effects on carotid IMT in metabolic syndrome, Circulation, 130, A1269. Abstract
  24. Finzi, 2009, Antiarrhythmic effects of n-3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI-HF trial, European Heart Journal, 30, 279
  25. Rovere, 2011, Effect of n-3PUFA on heart rate variability. Data from the GISSI-HF holter substudy, Circulation, 124, A14829
  26. Latini, 2011, Circulating levels of n-3 polyunsaturated fatty acids in patients with chronic heart failure. Data from the GISSI-HF trial, European Heart Journal, 32, 919
  27. Marchioli, 2009, Time course analysis of the effect of n-3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI-HF trial, European Heart Journal, 30, 165
  28. Marchioli, 2009, Time course analysis of the effect of n-3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI-HF trial, European Heart Journal, 30, 432
  29. Marchioli, 2009, Prognostic ability of a Mediterranean dietary score in heart failure: preliminary analysis of the GISSI-Heart failure Trial, European Heart Journal, 30, 1026
  30. Marchioli, 2009, Effect of n-3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI-heart failure trial, European Heart Journal, 30, 426
  31. Marchioli, 2009, Effect of n-3 PUFA according to fish intake: preliminary results of GISSI-Heart Failure, European Heart Journal, 30, 707
  32. Tan, 2010, Dietary Manipulation and Weight Management [PhD thesis]
  33. Delrieu, 2011, Multidomain alzheimer's disease preventive trial: florbetapir ancillary study, Alzheimer's and Dementia, 1, S419, 10.1016/j.jalz.2011.05.1217 · DOI
  34. Gillette, 2009, The multidomain Alzheimer preventive trial (MAPT): a new approach for the prevention of Alzheimer's disease, Alzheimer's & Dementia, S4-02-05, 145, 10.1016/j.jalz.2009.05.496 · DOI
  35. Gillette-Guyonnet, 2011, MAPT study: a 3-year randomized trial of omega 3 and/or multidomain intervention for the prevention of cognitive decline in frail elderly subjects-rationale, design and baseline data, Alzheimer's & Dementia, 1, S97
  36. Vellas, 2012, MAPT (multidomain Alzheimer preventive trial) imaging (MRI, FDG-PET, amyloid-PET) data, Journal of Nutrition, Health and Aging, 16, 812
  37. Pinto, 2015, Effect of low doses of long chain n-3 PUFA intake on daytime heart rate variability: results from the MARINA study, European Journal of Preventive Cardiology, 1, S146
  38. Nodari, 2010, Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in heart failure patients, European Heart Journal, 31, 850
  39. Nodari, 2012, Plasma levels of n-3 polyunsaturated fatty acids and risk of hospitalization in patients with non-ischemic cardiomyopathy, Circulation. Conference: American Heart Association, 126, A17431
  40. Ilsey, 1987, Randomised placebo controlled trial of MAXEPA and aspirin/persantin after successful coronary angioplasty, Australian & New Zealand Journal of Medicine, 17, 559
  41. Naesgaard, 2014, The effect on vitamin D levels of long-term high-dose treatment with a concentrated omega-3 compound (Omacor/Lovaza) in patients hospitalized with a myocardial infarction, Circulation, 130, A17245
  42. Poenitz, 2012, Pentraxin 3 is uninfluenced by high doses of concentrated omega-3 fatty acids administered for 12 months following an acute myocardial infarction, Circulation. Conference: American Heart Association, 126, A13464
  43. Bordeleau, 2013, Cancer outcomes in patients with dysglycemia on basal insulin: results of the Origin trial, Diabetes, 62, A72
  44. Proudman, 2012, Fish oil in rheumatoid arthritis: a randomised, double blind trial comparing high dose with low dose, Internal Medicine Journal, 42, 2
  45. Eritsland, 1994, Effect of supplementation with n-3 fatty acids on graft patency in patients undergoing coronary artery bypass operation. Results from SHOT study, European Heart Journal, 15, 29
  46. Eritsland, 1993, Long-term influence of omega-3 fatty acids on fibrinolysis, fibrinogen, and serum lipids, Thrombosis and Haemostasis, 69, 1065
  47. Galan, 2008, The SU.FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics, Trials, 9, 35, 10.1186/1745-6215-9-35 · DOI
  48. Galan, 2009, The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events, Sang Thrombose Vaisseaux, 21, 207
  49. Galan, 2009, The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events, Sang Thrombose Vaisseaux, 21, 207
  50. McCormick, 2015, Peripheral sensory nerve function is independently associated with microvascular function, but neither are improved by n-3 fatty acids, Diabetic Medicine, 32, 99
  51. Scorletti, 2014, Potential benefits of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and type 2 diabetes? Results from the WELCOME study, Diabetic Medicine, 31, 1
  52. Baleztena Gurrea, 2015, Utility of heavy food supplement in omega-3 fatty acids in the prevention of dementia, in relation to the basal nutritional level, in people of advanced age: randomized multicenter study, Revista Española de Geriatría y Gerontología, 50, 1
  53. Bes-Rastrollo, 2015, Utility of a rich food supplement Omega-3 fatty acids in the prevention of dementia, in relation to baseline nutritional level, in people with advanced age: multicentre randomised study, Nutrición Clínica en Medicina, 9, 38
  54. Cheng, 1990, The effect of omega-3 fatty acids on restenosis after coronary angioplasty, European Heart Journal, 11, 368
  55. Fonolla, 2011, Daily intake of a low lactose dairy drink enriched with omega-3 (EPA+DHA), oleic acid and calcium improves nutritional and bone status in healthy postmenopausal women, Clinical Nutrition, 6, 86
  56. Franzen, 1989, Long-term effect of fish oil and olive oil on plasma lipids in patients with CHD, Zeitschrift fur Kardiologie, 78, 28
  57. Gapparova, 2000, Effects of omega-3 polyunsaturated fatty acids of vegetable and animal origin on clinical and metabolic indicators and the intensity of lipid peroxidation in patients with ischemic heart disease and impaired carbohydrate tolerance, Voprosy Pitaniia, 69, 46
  58. Hashimoto, 2011, Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function in elderly people with very mild dementia in Japan, Alzheimer's and Dementia, 1, S610
  59. Hashimoto, 2012, Beneficial effects of daily dietary omega-3 polyunsaturated fatty acid supplementation on age related cognitive decline in elderly Japanese with very mild dementia: a 2-year randomized,double-blind, placebo-controlled trial, Journal of Aging Research & Clinical Practice, 1, 193
  60. Lau, 1991, Effects of Maxepa on non-steroidal anti-inflammatory drug useage in patients with mild rheumatoid arthritis, British Journal of Rheumatology, 30, 137
  61. Lorgeril, 1999, Does a Mediterranean dietary pattern prolong survival?, Cardiology Review, 16, 30
  62. Mantzaris, 1996, A prospective, randomized, placebo-controlled study of fish oil in ulcerative colitis, Hellenic Journal of Gastroenterology, 9, 138
  63. Mate, 1991, Does dietary fish oil maintain the remission of Crohn's disease: a study case control, Gastroenterology, 100, A228
  64. Colquhoun, 1997, Rationale and design of the "OLIVE" study (comparison of an olive oil enriched to a low fat diet intervention study using vascular endpoints), Atheroscerosis, 134, 326
  65. Colquhoun, 1998, Comparison of an olive oil enriched diet to a low fat diet intervention study using vascular endpoints: assessed by repeat quantitative angiography (OLIVE study), Australian Journal of Nutrition and Dietetics, 55, S24
  66. Meilahn, 1990, Coagulation parameters among healthy adults taking fish oil versus placebo, Arteriosclerosis, 10, 916A
  67. Singh, 2012, Effect of low W-6/W-3 fatty acid ratio Paleolithic style diet in patients with acute coronary syndromes: a randomized, single blind, controlled trial, World Heart Journal, 4, 71
  68. Singh, 1997, Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival 4, Cardiovascular Drugs and Therapy, 11, 485, 10.1023/A:1007757724505 · DOI · Paper page
  69. Bowman, 2012, ASCEND: design and baseline characteristics of a large randomised trial in diabetes, Diabetes, 61, A556
  70. Chandrakala, 2012, Low-fat (< 20%) diets prevent type 2 diabetes mellitus, Diabetes, 61, A190
  71. Laake, 2014, Effects of omega 3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study, BMC Geriatrics, 14, 74, 10.1186/1471-2318-14-74 · DOI
  72. Shinto, 2015, Omega 3 fatty acids for the prevention of vascular cognitive aging: methods and rationale for a phase II trial, Alzheimer's & Dementia, 11, 610, 10.1016/j.jalz.2015.06.847 · DOI
  73. Gold, 2014, Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega-3 trial, American Journal of Respiratory and Critical Care Medicine, 189, D44 COPD
  74. Kang, 2015, Cognitive substudy of the vitamin d and omega-3 trial (vital-cog): design of a large randomized trial of omega-3 and vitamin d supplements in relation to cognitive change, Alzheimer's & Dementia, 1, 608, 10.1016/j.jalz.2015.06.843 · DOI
  75. Manson, 2010, Vitamin D and cancer and cardiovascular disease: ready for prime time?, Menopause, 17, 1215
  76. Abdelhamid, 2017, Polyunsaturated fatty acids for musculoskeletal health and functional status in older adults, PROSPERO, www.crd.york.ac, CRD42017079211
  77. Hanson, 2017, Dietary polyunsaturated fat for prevention and treatment of depression and anxiety, PROSPERO, www.crd.york.ac, CRD42017056092
  78. Higgins JP Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
  79. Jimoh, 2017, Dietary polyunsaturated fat for prevention and treatment of neurocognitive disorders, PROSPERO, www.crd.york.ac, CRD42017019049
  80. Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
  81. Liem, 1997, Dioxins: Chemical Analysis, Exposure and Risk Assessment
  82. Mariani, 2013, N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials, Journal of the American Heart Association, 2, e005033, 10.1161/JAHA.112.005033 · DOI
  83. Thorpe, 2017, Dietary polyunsaturated fat for prevention and treatment of inflammatory bowel disease, PROSPERO, www.crd.york.ac, CRD42017068704

Cited by

See all 405

Metadata

Authors
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G. C., Moore, H. J., Deane, K. H., AlAbdulghafoor, F. K., Summerbell, C. D., Worthington, H. V., Song, F., & Hooper, L.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2018-11-30
Volume
11
Pages
CD003177-CD003177
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W4243760090
Cited by
405
References
443
FWCI
38.20
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. https://app.cochat.ai/papers/10.1002/14651858.cd003177.pub4
The paper
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G. C., Moore, H. J., Deane, K. H., AlAbdulghafoor, F. K., Summerbell, C. D., Worthington, H. V., Song, F., & Hooper, L. (2018). Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd003177.pub4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.